Investing.com - BioLineRx reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
BioLineRx announced earnings per share of $-0.1493 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.125 on revenue of $0.00.
BioLineRx shares are up 8.69% from the beginning of the year and are trading at $2.739 , down-from-52-week-high.They are under-performing the Nasdaq which is up 23.91% from the start of the year.
BioLineRx shares lost 1.12% in intra-day trade after the report.
BioLineRx follows other major Healthcare sector earnings this month
BioLineRx's report follows an earnings beat by Pfizer on Tuesday, November 2, 2021, who reported EPS of $1.34 on revenue of $24.09B, compared to forecasts EPS of $1.08 on revenue of $22.58B.
Novo Nordisk ADR had beat expectations on Wednesday, November 3, 2021 with third quarter EPS of $0.8209 on revenue of $5.55B, compared to forecast for EPS of $0.7768 on revenue of $5.39B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar